Objectives Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive ...
NEW YORK — Patients with rheumatoid arthritis (RA) carry a high risk for cardiovascular events, but mounting clinical evidence suggests they're being undertreated to manage that risk. Rheumatologists ...
CHICAGO — Anti-TNF biologic therapies are typically used first foradults aged 60 years or older with rheumatoid arthritis (RA), but many will need to switch to non-TNF biologics because of inadequate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback